Product Description
Mechanisms of Action: GLUN Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Germany | India | Lithuania | Portugal | Russia
Approved Indications: None
Known Adverse Events: None
Company: AWD
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Acute Pain|Spasm
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20131588 | P1 |
Active, not recruiting |
Acute Pain|Spasm |
None |
|
| CTR20131585 | P1 |
Active, not recruiting |
Acute Pain|Spasm |
None |
|
| CTR20131587 | P1 |
Active, not recruiting |
Spasm|Acute Pain |
None |